Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
